Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

This study is comparing two treatment combinations for people with marginal zone lymphoma (a slow-growing type of blood cancer) who have never been treated before: a newer regimen using orelabrutinib plus rituximab versus the standard R-CVP chemotherapy combination. **You may be eligible if...** - You are 18 or older - You have been confirmed to have CD20-positive marginal zone lymphoma (a type of lymph node cancer) - You have not had any previous systemic treatment for this condition - Your organs are functioning well enough to handle treatment - You are willing to use contraception during and for 8 weeks after the study **You may NOT be eligible if...** - The cancer has spread to your central nervous system (brain or spinal cord) - You have another untreated cancer - You have serious heart problems or other significant medical conditions - You have been previously treated for this lymphoma Talk to your doctor to see if this trial is right for you.